Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Lion, MedImmune pair up against cancer
February 2016
SHARING OPTIONS:

NEW YORK—Late December saw Lion Biotechnologies Inc. announce a collaboration to conduct clinical and preclinical research in immuno-oncology with MedImmune, the global biologics research and development arm of AstraZeneca. Preclinical research under the agreement will focus on identifying and evaluating therapeutically effective combinations of MedImmune’s checkpoint antibodies, using tumor-infiltrating lymphocytes (TIL) as an in-vitro model of the tumor microenvironment. The research will be funded by MedImmune and conducted by Lion. Also, Lion will fund and conduct two Phase 2a clinical trials combining MedImmune’s investigational PD-L1 inhibitor durvalumab with TIL for the treatment of patients with metastatic melanoma, and head and neck cancer. MedImmune will supply durvalumab for the clinical trials. The studies will establish a dosing regimen for this combination therapy and assess its safety and efficacy

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.